| BRIEF COMMUNICATION |
|
| Year : 2020 | Volume
: 30
| Issue : 3 | Page : 158-160 |
Glomerular diseases with reference to COVID-19
Sanjeev Gulati1, Narayan Prasad2, Manisha Sahay3, Vivek Kute4, Sanjay K Agarwal5, On behalf of COVID-19 Working Group of Indian Society of Nephrology6
1 Nephrology and Kidney Transplant Fortis Gp of Hospitals, New Delhi, India
2 Professor of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
3 Professor and Head, Osmania Medical College, Hyderabad, Telangana, India
4 Professorof Nephrology, IKDRC, Ahmedabad, Gujarat, India
5 AIIMS, New Delhi, India
6 ,
Correspondence Address:
Narayan Prasad
Department of Nephrology, Sanjay Gandhi Postgraduate, Institute of Medical Sciences, Lucknow 226 014, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijn.IJN_167_20
COVID pandemic affected every individual across the world. Patients with primary glomerular disease and glomerular disease secondary to systemic diseases who are on moderate to high doses of immunosuppression are at an increased risk of COVID because of their immunosuppressed state. The data to quantify the degree of risk in relation to the amount of immunosuppression or their duration of use is not robust. The patients on immunosuppression need to modify the drugs balancing the risk relapse and flare of the disease, simultaneously minimizing the risk of developing COVID. We tried to develop a guideline about the modification of the treatment regimen in such conditions.
[FULL TEXT] [PDF]*
|
|
Editorial Board
